Unlocking the power of mechano-biology to enhance the immune system. Lahara Bio is a pre-seed stage biotechnology company developing a new class of non-invasive therapeutics based on low-intensity vibration (LIV).
Lahara Bio is pioneering a new modality in medicine, that harnesses mechanical signals, not molecules, to modulate immunity. Spun out of decades of research in mechanobiology, our platform leverages the body’s natural responsiveness to mechanical stimulation to restore and enhance immune function. We are a team of scientists, engineers, and entrepreneurs advancing a therapeutic strategy that is safe, scalable, and rooted in physiology.
Our mission is to harness natural
cellular mechanosensitivity to
develop vibration as a novel
therapeutic modality, delivering
the benefits of exercise to
patients and cells on demand.
Lahara Bio’s technology is based on low-intensity vibration (LIV), a non-invasive mechanical signal that mimics the beneficial cellular forces generated during physical activity. Unlike traditional pharmacology, our approach delivers subtle, precisely tuned vibrations that engage immune cells at the level of their cytoskeleton, nucleus, and signaling networks.
Our foundational discovery is that immune cells are mechanosensitive to vibration. Through targeted mechanical stimulation, we can enhance activation, proliferation, and resilience of these cells, even in contexts where aging or cancer suppresses immune function.
By modulating mechanosensitive signaling pathways that are critical to cell survival, growth, and metabolism. LIV offers a novel, drug-free way to prevent immune exhaustion, restore activity to aged, senescent immune cells, and support cancer immunotherapies.
In the tumor microenvironment, immune cells are often suppressed or rendered dysfunctional. LIV restores T cell activity by mechanically engaging signaling pathways like AKT and mTOR, counteracting immune exhaustion and resistance. As a drug-free adjuvant, LIV has the potential to enhance the efficacy of checkpoint inhibitors and cellular therapies.
Aging impairs immune surveillance, reducing the body’s ability to prevent infection, clear senescent cells, and suppress cancer. LIV reactivates aged immune cells by mechanically turning on CD-28 costimulatory signaling pathways, offering a scalable, non-invasive approach to immune rejuvenation and healthspan extension.
Dr. Clint Rubin is a SUNY Distinguished Professor and the founding Chair of the Department of Biomedical Engineering at Stony Brook University. Internationally recognized for his work in mechanobiology and non-pharmacologic interventions, Dr. Rubin has authored over 300 peer-reviewed publications and holds more than 40 patents. He previously founded success ful medical device companies Exogen (acquired by Smith & Nephew), Juvent, and Marodyne Medica. Dr. Rubin brings decades of experience translating mechanical stimulation into clinically approved technologies.
Dr. Chris Ashdown is an MD/PhD physician-scientist candidate who completed his thesis dissertation under Dr. Rubin at Stony Brook University, where he developed low-intensity vibration (LIV) as a novel immunotherapeutic platform. His doctoral research focused on how mechanical signals can non-invasively enhance T cell activation and reverse age-related immune decline. Chris is the lead inventor on Lahara Bio’s core IP and brings expertise in immunology, device development, and translational science.
.png)
Michael R. Bielski, is a serial entrepreneur and C-level executive in the medical technology and biotechnology fields. Michael has brought technologies from early conception, development and patenting through manufacturing, the generation of licensing revenues, clinical use and sales. Michael is an experienced angel and venture capital fundraiser whose companies have raised over $75M in financing. Michael is an expert across all areas of high-technology commercialization including out-licensing and start-up company formation and operations.
© Lahara Bio, Inc. 2025.